Galena Biopharma, Inc. (NASDAQ:GALE) Files An 8-K Other EventsItem 8.01. Other Events.
On October2, 2017, SELLAS Life Sciences Group Ltd (“SELLAS”) issued a press release entitled “SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck& Co., Inc., Kenilworth, N.J., USA.” A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 8.01. Financial Statements and Exhibits.
Exhibit Index
|
ExhibitNo. |
Description |
| 99.1 | Press release, dated October 2, 2017. |
Galena Biopharma, Inc. ExhibitEX-99.1 2 d458739dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co.,…To view the full exhibit click here
About Galena Biopharma, Inc. (NASDAQ:GALE)
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.
